Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables R1, R2, R3, and R4 are as defined herein.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: The present technology provides systems and methods for reducing error rates to data input to a keyboard, such as a touch screen keyboard. In one example, an input bias model dynamically changes the keyboard functionality such that the keyboard will not necessarily produce the same result for an identical tap coordinate. Rather, the keyboard functionality is adapted to account for key offset bias that occurs when the user has a tendency to select a tap coordinate that would otherwise return an unintended key. Additionally, the present technology provides a language feedback model that may provide a probability for a next tap coordinate and may augment the key corresponding to the most probable next tap coordinate, thereby allowing the user to more easily select the correct key. Further details are provided herein.

Abstract: The present invention provides a facile process for the preparation of tri- and tetra—substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for treating or lessening the severity of Aurora—mediated diseases or conditions.

Abstract: A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims, comprises the step of: a) cyclizing a compound represented by Structural Formula A: under suitable reductive cyclisation conditions to form a compound represented by Structural Formula B: wherein R10 is LG1 or —X1R1, and -LG1 is a suitable leaving group; and b) optionally, when R10 of Structural Formula (B) is LG1, further comprising the step of replacing the -LG1 of Structural Formula (B) with —X1R1 to form the compound represented by Structural Formula (I).

Abstract: The present invention relates to compounds useful as inhibitors of PLK protein kinase of the following formula: or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: A charge/discharge input is for respectively supplying charge to, or drawing charge from, an electrochemical cell. A transition modifying circuit is coupled between the charge/discharge input and a terminal of the electrochemical cell and includes at least one of an inductive constituent, a capacitive constituent and a resistive constituent selected to generate an adjusted transition rate on the terminal sufficient to reduce degradation of a charge capacity characteristic of the electrochemical cell. A method determines characteristics of the transition modifying circuit. A degradation characteristic of the electrochemical cell is analyzed relative to a transition rate of the charge/discharge input applied to the electrochemical cell. An adjusted transition rate is determined for a signal to be applied to the electrochemical cell that will reduce the degradation characteristic.

Abstract: Systems and methods for intelligent language models that can be used across multiple devices are provided. Some embodiments provide for a client-server system for integrating change events from each device running a local language processing system into a master language model. The change events can be integrated, not only into the master model, but also into each of the other local language models. As a result, some embodiments enable restoration to new devices as well as synchronization of usage across multiple devices. In addition, real-time messaging can be used on selected messages to ensure that high priority change events are updated quickly across all active devices. Using a subscription model driven by a server infrastructure, utilization logic on the client side can also drive selective language model updates.

Abstract: A gate valve comprises a valve body having an internal working fluid passage and an internal gate chamber extending transverse to the working fluid passage. In addition, the gate valve comprises a gate disposed in the internal gate chamber and movable within the gate chamber between a closed position obstructing fluid flow through the working fluid passage and an open position allowing fluid flow through the working fluid passage. Further, the gate valve comprises an internal sealing arrangement coaxially disposed in the working fluid passage and extending between the valve body and the gate to form a barrier between the internal working fluid passage and the gate chamber. The internal sealing arrangement includes a frustoconical metal sealing surface adapted to sealingly engage an opposed mating frustoconical metal sealing surface on the valve body to form a first tapered metal-to-metal seal between the sealing arrangement and the valve body.

Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims, comprises the step of: a) cyclizing a compound represented by Structural Formula A: under suitable reductive cyclization conditions to form a compound represented by Structural Formula B: wherein R10 is LG1 or —X1R1, and -LG1 is a suitable leaving group; and b) optionally, when R10 of Structural Formula (B) is LG1, further comprising the step of replacing the -LG1 of Structural Formula (B) with —X1R1 to form the compound represented by Structural Formula (I).

Abstract: A system and method for stabilization of an image capture device are disclosed. Also disclosed are a system and method for autofocus of an image capture device.

Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

Abstract: This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2?, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Abstract: The present invention relates to compounds useful as inhibitors of protein kinase, represented by Structural Formula (I): wherein the variables in Structural Formula (I) are as described herein. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

Abstract: The subject disclosure relates to techniques for monitoring contextual and performance information of a device for anticipatorily sending update information to the device. An interface component can receive, from the client, contextual information indicating an operating environment of the client and performance information that is associated with one or more operations being performed by the client based on the operating environment, and send, based on correlation information, update information to the client. Further, a service component can to infer a relationship between the contextual information and the performance information to obtain the correlation information. In other embodiments, a client can populate a cache with portion(s) of the contextual information to obtain cached information, and send at least a portion of the cached information to a system including one or more aspects of the service component.

Abstract: Regulatory compliance techniques are provided for dynamically modifying access to data based on the jurisdiction a user seeking access to the data is located within. Dynamically modifying access to data provides for a more efficient and accurate solution to regulatory compliance issues faced when hosting data in a central repository. Users can be notified when their access to data is modified due to a compliance issue. In addition, an audit history can be associated with data packets that allow an administrator or the like to view the history of data packet access. Finally, signatures associated with a data packet can be used to search data store(s) to track access to information within the data packet that may have been subsequently modified.

Abstract: The subject disclosure generally relates to provisioning devices via a network service, such as a cloud service. A profile component can authenticate a user of a device with a cloud service, and determine services maintained by the network service that are associated with the user. A reception component can receive a request for a set of services from the device, and a services component can obtain the set of services from the network service, and provision the device based on the set of services. Provisioning the device can include downloading the services to the device, or including the services in a virtual machine executing in the network service.

Abstract: The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R1, and R2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.